Article ID Journal Published Year Pages File Type
8485512 Vaccine 2018 6 Pages PDF
Abstract
These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , ,